5 Short Squeeze Candidates To Watch: Ambrx Biopharma, Kala Pharmaceuticals And This Company That Moved Up 1,403 Positions

Zinger Key Points
  • A new stock tops the short squeeze leaderboard, moving up 766 positions.
  • Three of the top five candidates appeared on last week's list.

Potential short squeeze plays gained steam in 2021 and continued through 2022, with new traders looking for the next huge move.

High short interest and a high cost to borrow are among the common traits that could lead to a short squeeze.

Here’s a look at the top five short squeeze candidates this week based on the Fintel short squeeze leaderboard.

Related Link: What Is A Short Squeeze?

  • Ambrx Biophrama AMAM: Biopharmaceutical company jumps 766 places to top the short squeeze leaderboard for the week. Data shows 96.3% of the float short and a cost to borrow of 86%. Shares saw a big jump recently on news of a stock exchange transfer from the New York Stock Exchange to the Nasdaq. The ticker was also the 19th most searched stock on Benzinga Pro in the month of February.
  • Kala Pharmaceuticals KALA: No stranger to the short squeeze leaderboard, Kala Pharmaceuticals ranks second for the second straight week on the leaderboard. Data shows 14.2% of the float short, up from last week’s 12.9% reported. The cost to borrow on shares is 507%, up from last week’s 227.8% reported.
  • MoonLake Immunotherapeutics MLTX: Biopharmaceutical company moves up two positions from last week’s fifth place listing. Data shows 17.8% of the float short, up from last week’s 12.3% reported. The cost to borrow on shares is 14.4%, down from last week’s 15.4%.
  • iBio Inc IBIO: The healthcare company ranks fourth on the short squeeze leaderboard for a second straight week. Data shows 16.6% of the float short, down from last week’s 17.6% reported. The cost to borrow on shares is 245.7%, down from last week’s 305.2%.
  • Cingulate Inc CING: Biopharmaceutical company moves up 1,403 positions to fifth place on the leaderboard. Data shows 12.5% of the float short and a cost to borrow of 198.8%. Shares of Cingulate rocketed higher in late February after announcing positive topline results for its lead candidate CTx-1301.

Next: Benzinga's 'Stock Whisper Index' - 5 Stocks Investors Are Secretly Monitoring But Not Yet Talking About

Market News and Data brought to you by Benzinga APIs
Posted In: NewsPenny StocksSmall CapTrading IdeasBiotech StocksFintelFintel short sqeueezeShort Squeezeshort squeeze candidatesShort squeeze ideas
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...